FamiCordTx
FamiCordTx is a Polish biotech subsidiary of the FamiCord Group developing allogeneic CAR-T cell therapies from cord blood for blood cancer patients. The pre-clinical company is grant-funded by Poland's Medical Research Agency and targets B-cell malignancies with off-the-shelf administration.
- Company typePrivate
- Founded2019
- HeadquartersWarsaw, Poland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What FamiCordTx does
FamiCordTx S.A. is a Polish clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for the treatment of hematological malignancies, with a primary focus on B-cell cancers. The company was founded in 2019 as a subsidiary of the FamiCord capital group, which has over 20 years of operating history and is associated with umbilical cord blood banking infrastructure. Its core technology combines cell therapy and genetic engineering, using allogeneic effector lymphocytes sourced from cord blood and engineered to express CAR receptors (including CD19-targeting constructs) to create what the company describes as the world's first off-the-shelf allogeneic populational bank CAR-T therapy designed for immediate administration.
The technical platform addresses known limitations of autologous CAR-T approaches — namely individualized manufacturing delays, high cost, and exclusion of patients too severely ill to wait for personalized production. The portfolio includes an allogeneic CAR-T cancer therapy product, a targeted ex-vivo gene therapy program, and the allogeneic effector lymphocyte platform itself. Manufacturing is intended to comply with GMP standards, and the scientific team is described as internationally sourced (US, Poland, Australia) with embedded PhD programs, though no named principal investigators or management roster is disclosed.
The business model is currently grant-funded rather than revenue-generating. The company does not publicly disclose pricing, and its only disclosed monetary inflow is a PLN 20,802,247.86 (~USD 5M) grant from Poland's Medical Research Agency (Agencja Badań Medycznych) awarded in 2022 under the ABM/2022/6 program for targeted/personalized medicine based on nucleic acid therapies, against a total project value of PLN 44,541,120.72. Distribution upon commercialization is expected to flow through hospitals, cancer treatment centers, and hematology departments, but no commercial customers, headcount figures, or product launch dates are disclosed.
FamiCordTx firmographics
Firmographics- Name
- FamiCordTx
- Legal name
- FamiCordTx S.A.
- Website
- https://famicordtx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- FamiCordTx is a Polish biotech subsidiary of the FamiCord Group developing allogeneic CAR-T cell therapies from cord blood for blood cancer patients. The pre-clinical company is grant-funded by Poland's Medical Research Agency and targets B-cell malignancies with off-the-shelf administration.
- Ownership category
- akta.pro rank
FamiCordTx industry classification
Industry- Product category
- Cell and Gene Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where FamiCordTx is headquartered
LocationHeadquarters
- HQ city
- Warsaw
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
FamiCordTx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain
Distribution channels1 record
Marketing channels1 record
FamiCordTx product offering
Product offeringCore offering
FamiCordTx develops allogeneic (off-the-shelf) CAR-T cell therapies and ex-vivo gene therapies built on cord blood–derived effector lymphocytes to treat hematological malignancies. Its pipeline targets relapsed/refractory B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma using standardized cellular drug products manufactured from umbilical cord blood rather than patient-autologous cells. The company operates as a clinical-stage biopharmaceutical developer leveraging its FamiCord Group parent's cord blood supply for scalable raw material access.
Product overview
FamiCordTx is a biotech company developing a portfolio of allogeneic cell and gene therapies focused on CAR-T cancer treatment. The company's core product is an allogeneic CAR-T therapy based on a populational bank of cord blood-derived effector lymphocytes, designed to provide immediate off-the-shelf administration to patients with B-cell malignancies. The product portfolio includes CAR-T cancer therapy and ex-vivo gene therapy platforms, with the goal of making advanced gene and cell therapies accessible for everyone.
Differentiator
Problem solved
Functional benefit
Products and services
- CAR-T Cancer Therapy (allogeneic) Allogeneic (off-the-shelf) CAR-T cell therapy targeting hematological malignancies including relapsed/refractory B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma; intended for licensing or clinical development partners and, post-approval, hospital-based oncology centers.
- Ex-Vivo Gene Therapy Ex-vivo gene therapy platform utilizing cord blood–derived effector lymphocytes as the cellular substrate for genetic modification, intended to extend the company's cellular immunotherapy capabilities beyond CAR-T into broader engineered cell therapies.
- Allogeneic Effector Lymphocytes (cellular drug product) Off-the-shelf allogeneic effector lymphocytes isolated and expanded from umbilical cord blood, serving as the standardized cellular starting material for both the allogeneic CAR-T and ex-vivo gene therapy programs.
Companies that use FamiCordTx
Customer profileSegments1 record
Ideal customer profiles1 record
FamiCordTx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
FamiCordTx partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights4 records
FamiCordTx competitors and assessment
Company assessmentDirect peers
- Allogene Therapeutics: Clinical-stage leader in allogeneic CAR-T cell therapy targeting CD19 and BCMA for hematological malignancies. Most directly comparable peer — both companies pursue off-the-shelf allogeneic CAR-T architectures, though Allogene uses peripheral blood-derived T-cells rather than cord blood.
- Cellectis: Pioneer in gene-edited allogeneic CAR-T using TALEN-based cell engineering, with clinical programs in B-cell malignancies and partnerships with Allogene and Servier. Direct competitor building off-the-shelf CAR-T banks with gene-editing platforms similar in spirit to FamiCordTx's populational bank approach.
- CRISPR Therapeutics: Develops allogeneic CAR-T therapies (CTX110 for CD19) using CRISPR/Cas9 gene editing to create off-the-shelf products. Direct competitor in the allogeneic CAR-T space with significant capital and a Vertex partnership; competes for the same off-the-shelf value proposition.
Peers
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights3 records
Customer concentration
FamiCordTx social profiles
Digital presenceFamiCordTx financial estimates
Financial estimateRevenue estimate
Valuation estimate
FamiCordTx leadership team
Management profileNumber of profiles
Profiles1 record
FamiCordTx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FamiCordTx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FamiCordTx
What does FamiCordTx do?
FamiCordTx develops allogeneic (off-the-shelf) CAR-T cell therapies and ex-vivo gene therapies built on cord blood–derived effector lymphocytes to treat hematological malignancies. Its pipeline targets relapsed/refractory B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma using standardized cellular drug products manufactured from umbilical cord blood rather than patient-autologous cells. The company operates as a clinical-stage biopharmaceutical developer leveraging its FamiCord Group parent's cord blood supply for scalable raw material access.
Is FamiCordTx a public or private company?
FamiCordTx is a private company. It is classified as corporate owned and is currently operating.
When was FamiCordTx founded?
FamiCordTx was founded in 2019. It employs 11 to 50 people.
Where is FamiCordTx based?
FamiCordTx is headquartered in Warsaw, Poland, in the Europe region.
Who are FamiCordTx's main competitors?
Direct peers on record are Allogene Therapeutics, Cellectis and CRISPR Therapeutics. Precision BioSciences is listed as a peer.
Does FamiCordTx have an API?
No public API is recorded for FamiCordTx.
What industry is FamiCordTx in?
FamiCordTx's product category is Cell and Gene Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.